Can volixibat and brelovitug expand Mirum Pharmaceuticals’ rare liver disease ambitions?
Mirum Pharmaceuticals’ EASL 2026 data deepen its rare liver disease strategy. Find out what changes for PSC, HDV and PFIC care.
Zydus gains FDA Priority Review for saroglitazar as PBC treatment competition intensifies
Zydus’ saroglitazar gets FDA Priority Review in PBC, setting up a key test for dual PPAR therapy in rare liver disease.
Is volixibat the next major growth lever for Mirum Pharmaceuticals beyond LIVMARLI?
Mirum has commercial momentum. VISTAS will test whether volixibat can extend that rare liver disease story into PSC.
What Mirum’s Bluejay acquisition reveals about its long-term liver disease strategy
Mirum adds brelovitug in HDV through Bluejay deal. See how this could redefine rare liver disease leadership ahead of AZURE Phase 3 results in 2026.